Global Myasthenia Gravis Diagnosis and Treatment Market Report 2022 to 2028 - North America is Anticipated to Hold a Considerable Market Share - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jan 6, 2023--
The “Global Myasthenia Gravis Diagnosis and Treatment Market Forecast, 2022-2028” report has been added to ResearchAndMarkets.com’s offering.
The global MG diagnosis and treatment market is anticipated to grow at a substantial CAGR of 7.9% during the forecast period.
- Amneal Pharmaceuticals, Inc.
- Argenx SE
- Astellas Pharma, Inc.
- Avadel Pharmaceuticals PLC
- Bausch Health Companies Inc.
- Baxter International, Inc.
- CSL Behring
- CuraVac, Inc.
- GlaxoSmithKline plc
- Immunovant, Inc.
- Mitsubishi Tanabe Pharma Corp.
- Ra Pharmaceuticals, Inc.
- Takeda Pharmaceutical Co., Ltd.
- UCB Pharma
- Valeant Pharmaceuticals International, Inc.
Myasthenia gravis is a chronic autoimmune, neuromuscular disorder that leads to weakness in the skeletal muscles. The eyes, face, and swallowing tubes are the most affected muscles. Increasing awareness related to rare diseases is growing the market for global myasthenia gravis diagnosis and treatment.
This disease is caused by an abnormal immune reaction (antibody-mediated autoimmune response) in which the body’s immune defenses (i.e., antibodies) inappropriately attack certain proteins in muscles that receive nerve impulses.
Factors such as antibodies and the thymus gland are predicted to be caused by myasthenia gravis. According to the Myasthenia Gravis Foundation Of America, around 14-20% of cases per 100,000 population in the US, which is around 36,000 to 60,000 cases in the US.
Impact of COVID-19 Pandemic on Global Myasthenia Gravis (MG) Diagnosis and Treatment Market
During the COVID-19 pandemic, limited transportation options and travel restrictions created hurdles to patients, international trade, and transportation, which disrupted the market for the myasthenia gravis diagnosis and treatment market. Patients’ and doctors’ footfall in the hospital declined during the pandemic which severely affected the patient’s and myasthenia gravis diagnosis and treatment market.
Many patients had faced challenges in getting proper medical care due to the pandemic. Diagnosis and treatment were majority put on hold at hospitals and diagnostics centers. Moreover, many manufacturers faced supply chain issues and hurdles during the pandemic.
The global MG diagnosis and treatment market is segmented based on treatment, diagnosis, and end-users. Based on the treatment, the market is segmented into medication, surgery, and others. Based on the diagnosis, the market is sub-segmented into edrophonium tests, blood tests, pulmonary function tests, electrodiagnostic, imaging, and others. Further, based on the end-users, the market is augmented into hospitals, clinics, and others.
Among the end-users, the hospitals are anticipated to hold a prominent market share. As patients mostly visit the hospital for diagnosis and treatment of the disease due to the presence of advanced equipment and proper guidance and consultation related to the disease.
The Medication Segment is Expected to Hold a Prominent Share in the Global Myasthenia Gravis (MG) Diagnosis and Treatment Market
The high intake of drugs to manage the associated symptoms of MG is a key factor contributing to the high market share of this market segment. Immunosuppressive drugs such as tacrolimus and cyclosporine and immunotherapies such as eculizumab and corticosteroids are the major medications taken by myasthenia gravis patients. The presence of a robust product pipeline of drugs used in the treatment of myasthenia gravis is anticipated to drive the growth of this market segment. For instance, IVIG treatment provides safe and effective long-term therapy for patients who are not benefited from conventional therapies.
The global MG diagnosis and treatment market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East &Africa, and Latin America). The market can be analyzed for a particular region or country level as per the requirement.
North America is anticipated to hold a considerable market share during the forecast period. High healthcare spending, the presence of cohesive government policies for R&D related to the myasthenia gravis treatment along with the presence of a huge patient pool are anticipated to be the key factors contributing to the high share of the North America region. According to the National Organization for Rare Disorders (NORD), in the US around 14-40 per 100,000 individuals suffer from myasthenia gravis on an annual basis. These factors will contribute to the growth of the market.
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global myasthenia gravis (MG) diagnosis and treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
For more information about this report visit https://www.researchandmarkets.com/r/etkvqy
View source version on businesswire.com:https://www.businesswire.com/news/home/20230106005183/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2023.
PUB: 01/06/2023 06:21 AM/DISC: 01/06/2023 06:21 AM